Fig 1

Fig 1. From: BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi.

Composite of genomic and immunohistochemical staining with representative cases with/without BRAF V600E mutation and positive/negative IGFBP7 expression. (a) Atypical genital naevus with moderate cytological atypia, with (b) BRAF V600E mutation and (c) positive IGFBP7 expression. (d) Atypical genital naevus with moderate cytological atypia, with (e) BRAF V600E mutation and (f) negative IGFBP7 expression. (g) Atypical genital compound melanocytic neoplasm with moderate to severe atypia, with (h) BRAF wild-type (WT) and (i) positive IGFBP7 expression. (j) Compound melanocytic naevus with features suggestive of congenital onset, with (k) BRAF V600E mutation and (l) positive IGFBP7 expression. (a, d, g, j) Haematoxylin and eosin; original magnification × 20.

L.P. Nguyen, et al. Br J Dermatol. ;162(3):677-680.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk